摘要
用微生物法测定了MSALVLX在狗体内的药代动力学过程符合二室模型。4、8和16mg/kg口服给药的Cmax分别为1.73、2.89和8.28mg/L,AUC值分别为15.43、31.95和70.2mgh/L,MRT分别为6.96、7.58和6628h。大鼠口服20mg/kg的Cmax为2.86mg/L,t1/2β为2.2h,AUC为7.4mgh/L,MRT为3h。大鼠口服后72h的尿中排泄率为42%,而72h胆汁排泄率为38.2%。
The pharmacokinetics of levofloxacin mesylate (MSALVLX) determined by microbiological assay in dogs fitted with a twocompartment model. Following single oral doses of 4, 8 and 16mg/kg, Cmax were 1.73, 2.89 and 8.28 mg/L respectively; t1/2 were 3 ̄6h; AUC were 15.43, 31.95 and 8.28 mgh/L respectively; MRT were independent of doses, and corresponding values were 6.96, 7.58 and 6.28 h. After a single oral administration of MSALVLX at a dose of 20mg/kg in rats, Cmax was 2.86 mg/L, t1/2 was 2.2h, AUC was 7.4 mgh/L, MRT was 3h. Accumulative urinary and biliary excretions was 42% and 38.2% within 72h after oral administration in rats.
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
1999年第3期205-207,238,共4页
Chinese Journal of Antibiotics
关键词
利复星
MSALVLX
药代动力学
血药浓度
Levofloxacin mesylate (MSALVLX)
Blood concentration,Microbiological assay,Pharmacokinetic parameter,Excretion